scholarly journals Using the Systemic Inflammation Index (SII) as a Mid-Treatment Marker for Overall Survival among Patients Undergoing Chemo-Radiation Therapy for Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC): Secondary Analysis of PROCLAIM Trial

2020 ◽  
Vol 108 (3) ◽  
pp. S103-S104
Author(s):  
T. Biswas ◽  
K.H. Kang ◽  
D. Bajor ◽  
M. Machtay ◽  
J.T. Efird
Sign in / Sign up

Export Citation Format

Share Document